10 November 2020 - Positive CADTH recommendation moves Duobrii closer to federal, provincial and territorial drug plan reimbursement. ...
30 October 2020 - The CADTH Canadian Drug Expert Committee has recommended that halobetasol (ulobetasol) propionate with tazarotene (Duobrii) be reimbursed ...
29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible ...
22 October 2020 - The first submission was withdrawn. ...
22 October 2020 - CADTH has finalised its assessment of eculizumab for adult patients with refractory generalised myasthenia gravis. ...
5 October 2020 - Positive recommendation by CADTH speaks to evidence and clinical benefit of Beovu. ...
1 September 2020 - The CADTH Canadian Drug Expert Committee has recommended that caplacizumab not be reimbursed for the treatment of ...
24 August 2020 - The new indication is for the treatment of patients with neuromyelitis optica spectrum disorder. ...
24 July 2020 - Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) is indicated as a complete regimen for the treatment ...
26 July 2020 - Final recommendation informed by input from Migraine Canada and Migraine Quebec. ...
23 July 2020 - The recommendation relates to the use of siponomid for the treatment of patients with secondary progressive multiple ...
20 July 2020 - CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. ...
20 July 2020 - CADTH has completed its assessment of ustekinumab by intravenous injection for the treatment of adult patients ...
14 July 2020 - The Institut national d'excellence en santé et en services sociaux (INESSS) recommends extending existing coverage in Quebec ...
1 June 2020 - CADTH has completed its assessment of burosumab for the treatment of patients with X-linked hypophosphatemia. ...